RxDoctor Payments Data

Laurie Corbitt

Women's Health · Rogers, ARNPI 1588622039

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 27.5% of the total.

$1,642in general payments, 2019–2025

Across 86 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$451
  • Exeltis, USA Inc.$232
  • Sumitomo Pharma America, Inc.$203
  • Astellas Pharma US Inc$177
  • Pfizer$149
  • Myovant Sciences Inc.$145
  • plus $284 from 5 others

What the payments were for

  • Food & beverage$1,54294%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,642 in reported general payments places this provider in the 80th percentile of 44 women's health providers in Arkansas.

See all women's health providers in Arkansas

Medicare billing

Part B allowed, 2024
$8,904
Medicare patients
126
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated14$5,672
Estradiol76$3,636
YuvafemEstradiol21$3,229
Estradiol (Once Weekly)Estradiol24$2,389
Clobetasol Propionate36$1,543
ValacyclovirValacyclovir Hcl20$888
Estradiol (Twice Weekly)Estradiol11$781
Norethindrone26$469
Medroxyprogesterone Acetate34$352
Escitalopram Oxalate16$321
Fluconazole17$67
Alendronate Sodium17$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$149$5,67214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 44 women's health providers in Arkansas.

Other women's health in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →